Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
作者信息
Park Jeong Su, Bae Soo Han
机构信息
Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2020 Oct;26(4):577-578. doi: 10.3350/cmh.2020.0143. Epub 2020 Sep 17.
Abstract
摘要
相似文献
1
Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?磷酸肌醇3激酶抑制剂是治疗肝细胞癌的有效治疗药物吗？
Clin Mol Hepatol. 2020 Oct;26(4):577-578. doi: 10.3350/cmh.2020.0143. Epub 2020 Sep 17.
2
Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma.靶向肝细胞癌中的上皮-间质转化途径。
Clin Mol Hepatol. 2020 Oct;26(4):484-486. doi: 10.3350/cmh.2020.0220. Epub 2020 Oct 1.
3
PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma.PI3Kα抑制剂损害AKT磷酸化，并在人肝细胞癌中与新型血管生成抑制剂AL3810协同作用。
Signal Transduct Target Ther. 2021 Mar 31;6(1):130. doi: 10.1038/s41392-021-00522-6.
4
Aspidin PB, a phloroglucinol derivative, induces apoptosis in human hepatocarcinoma HepG2 cells by modulating PI3K/Akt/GSK3β pathway.牡荆素 PB，一种间苯三酚衍生物，通过调节 PI3K/Akt/GSK3β 通路诱导人肝癌 HepG2 细胞凋亡。
Chem Biol Interact. 2013 Jan 25;201(1-3):1-8. doi: 10.1016/j.cbi.2012.11.005. Epub 2012 Nov 21.
5
A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation.羽扇豆醇通过抑制脑源性神经营养因子和再激活糖原合成酶激酶 3β诱导肝癌细胞凋亡的新机制。
Eur J Pharmacol. 2015 Sep 5;762:55-62. doi: 10.1016/j.ejphar.2015.05.030. Epub 2015 May 21.
6
Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells.曲格列酮通过 PI3K/Akt、GSK-3β、Snail1 和β-catenin 改善高糖诱导的肾小管上皮细胞转分化和 SGLTs 功能障碍。
Am J Physiol Renal Physiol. 2010 May;298(5):F1263-75. doi: 10.1152/ajprenal.00475.2009. Epub 2009 Dec 16.
7
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.“同类首创”双PI3K/BRD4抑制剂SF1126与索拉非尼在肝细胞癌中的单药活性及协同活性
Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5.
8
Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.苯磺酰胺衍生物作为对肝细胞癌具有体内疗效的强效PI3K/mTOR双重抑制剂的发现。
Bioorg Med Chem. 2016 Mar 1;24(5):957-66. doi: 10.1016/j.bmc.2016.01.008. Epub 2016 Jan 6.
9
Brain-derived Neurotrophic Factor Promotes Growth of Neurons and Neural Stem Cells Possibly by Triggering the Phosphoinositide 3-Kinase/ AKT/Glycogen Synthase Kinase-3β/β-catenin Pathway.脑源性神经营养因子可能通过触发磷酯酰肌醇 3-激酶/蛋白激酶 B/糖原合成酶激酶 3β/β-连环蛋白通路促进神经元和神经干细胞的生长。
CNS Neurol Disord Drug Targets. 2017;16(7):828-836. doi: 10.2174/1871527316666170518170422.
10
Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.肝细胞癌细胞中糖原合酶激酶-3β信号通路的失调
Hepatology. 2002 Dec;36(6):1528-36. doi: 10.1053/jhep.2002.37192.
引用本文的文献
1
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1.二甲双胍和二氯乙酸通过抑制 mTOR 复合物 1 抑制肝癌细胞增殖。
Int J Mol Sci. 2021 Sep 17;22(18):10027. doi: 10.3390/ijms221810027.
本文引用的文献
1
Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway.抑制 PI3K/Akt 信号通路通过 Snail/GSK-3/beta-catenin 通路抑制肝癌中的上皮间质转化。
Clin Mol Hepatol. 2020 Oct;26(4):529-539. doi: 10.3350/cmh.2019.0056n. Epub 2020 Aug 24.
2
Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.PI3K/AKT/mTOR信号通路在神经退行性疾病和肿瘤中的作用。
Cell Biosci. 2020 Apr 1;10(1):54. doi: 10.1186/s13578-020-00416-0. eCollection 2020.
3
PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.PI3Kδ 在肝细胞癌中是一个治疗靶点。
Hepatology. 2018 Dec;68(6):2285-2300. doi: 10.1002/hep.30307. Epub 2018 Nov 8.
4
Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIP in hepatocellular carcinoma.糖原合酶激酶-3β抑制促进肝癌细胞中 c-FLIP 的溶酶体依赖性降解。
Cell Death Dis. 2018 Feb 14;9(2):230. doi: 10.1038/s41419-018-0309-3.
5
The PI3K Pathway in Human Disease.人类疾病中的PI3K信号通路。
Cell. 2017 Aug 10;170(4):605-635. doi: 10.1016/j.cell.2017.07.029.
6
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma.糖原合酶-3在肝细胞癌中的关键作用。
Adv Biol Regul. 2017 Aug;65:59-76. doi: 10.1016/j.jbior.2017.06.002. Epub 2017 Jun 6.
7
RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.RBMY，一种糖原合成酶激酶 3β的新型抑制剂，增加肿瘤干细胞特性并预测肝细胞癌的不良预后。
Hepatology. 2015 Nov;62(5):1480-96. doi: 10.1002/hep.27996. Epub 2015 Aug 25.
8
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.idelalisib：用于治疗慢性淋巴细胞白血病、小淋巴细胞白血病和滤泡性淋巴瘤的首款PI3Kδ抑制剂。
Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10.
9
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.PI(3)K p110δ 的失活破坏了调节性 T 细胞介导的对癌症的免疫耐受。
Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.
10
Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy.结节性硬化症复合征 2 与糖原合成酶激酶 3β水平的相关性及其与肝癌患者肝切除术后结局的关系。
Hepatol Res. 2014 Oct;44(11):1142-50. doi: 10.1111/hepr.12256. Epub 2013 Nov 8.
Zotero 插件